| Similar Articles |
|---|
 |
American Family Physician
November 15, 2005
Goldman-Levine & Bohlman |
STEPS Review of the drug EZetimibe/Simvastatin used for hypercholesterolemia.   |
American Family Physician
July 15, 2005
Lee Radosh |
STEPS: Colesevelam (WelChol) for Reduction of LDL Cholesterol Colesevelam lowers LDL cholesterol levels a small amount (7% to 16%) when used alone and provides additional cholesterol lowering when added to statin therapy. |
Nurse Practitioner
July 2010
Kristine A. Scordo |
Treating antiretroviral-induced dyslipidemia in HIV-infected adults Studies indicate that HIV-infected patients (both males and females) may be at an increased risk for the development of cardiovascular disease |
American Family Physician
January 15, 2001
Michael A. Crouch |
Effective Use of Statins to Prevent Coronary Heart Disease Primary and secondary prevention trials have shown that use of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (also known as statins) to lower an elevated low-density lipoprotein level can substantially reduce coronary events and death from coronary heart disease... |
American Family Physician
January 15, 2002
Lori J. Mosca |
Optimal Management of Cholesterol Levels and the Prevention of Coronary Heart Disease in Women Elevated levels of low-density lipoprotein cholesterol and triglycerides and low levels of high-density lipoprotein cholesterol are significant risk factors for coronary heart disease. Abundant data show inadequate utilization of lipid-lowering therapy in women... |
American Family Physician
December 15, 2000
Alan J. Garber |
Attenuating Cardiovascular Risk Factors in Patients with Type 2 Diabetes All cardiovascular risk factors except smoking are more prevalent in patients with type 2 diabetes. In addition to exercise, weight control, aspirin therapy and blood pressure control, therapy to modify lipid profiles is usually necessary... |
American Family Physician
March 15, 2005
Lockman et al. |
Treatment of Cholesterol Abnormalities The relationship between coronary heart disease and elevated cholesterol levels has been recognized for many years, but now studies show an improvement in patient-oriented outcomes in patients receiving drug therapy. |
American Family Physician
March 1, 2002
Richard S. Safeer |
Cholesterol Treatment Guidelines Update In addition to modifying current strategies of risk assessment, the new guidelines stress the importance of an aggressive therapeutic approach in the management of hypercholesterolemia... |
Nurse Practitioner
February 2011
Jennifer M. Belavic |
Annual Drug Update: 2010 in Review In 2010, the FDA approved several new drugs and new indications for use in primary care. From new therapies for adults with rheumatoid arthritis to a combination drug for benign prostatic hyperplasia, NPs need to be aware of the latest medications now available. |
Nursing
February 2010
Daniel A. Hussar |
New Drugs 2010, PART 1 In this article, you'll learn about 16 new drugs. |
Nursing
March 2012
Daniel A. Hussar |
New Drugs 2012: part I In this article, you'll learn about 11 recently approved drugs. |
Nursing
June 2010
Daniel A. Hussar |
New drugs 2010, part 2 In this article, you'll learn about 14 recently marketed new drugs. |
Nursing
June 2011
Daniel A. Hussar |
New Drugs 2011: Part 2 In this article, you'll learn about seven recently approved drugs, including: fingolimod hydrochloride, an oral drug indicated to treat patients with relapsing forms of multiple sclerosis. |
Nursing
February 2009
Daniel A. Hussar |
New Drugs 09: Part 1 Learn about 10 new drugs, including nebivolol HCl, the newest beta-adrenergic blocking agent for hypertension. |
The Motley Fool
December 30, 2003
Arash Mostaghimi |
Turning Cholesterol Into Cash With 62 million Americans suffering from heart disease, it's a huge target for major drug makers. |
The Motley Fool
December 23, 2003
Arash Mostaghimi |
The Cholesterol Wars Who will win the fight to save your arteries? Fortunately for our corpulent country, pharmaceutical companies want to unclog our arteries -- and lighten our wallets. But which pharma stock will add to most girth to a portfolio? |
Chemistry World
May 2008
Derek Lowe |
In the pipeline The controversy over cholesterol drug Vytorin has been going on for months. Surveying the wreckage, my first thought is: what a terrible shame the whole affair is. |
Chemistry World
September 18, 2015
Rebecca Trager |
Amgen expands cardiovascular portfolio with Dezima acquisition Dezima's lead molecule is the cholesterol-lowering drug TA-8995. |
Managed Care
April 2004
Jack McCain |
Statin Therapy: More Than Meets the Eye? Statin selection has just become more complicated. Will physicians be diverted from interventions that may be less costly and just as effective? |
The Motley Fool
April 2, 2008
Michael P. Cecil |
Irrational Exuberance for Vytorin and Zetia? Drugmakers Merck and Schering-Plough certainly hoped data from the Enhance study would enhance the value and status of their blockbuster cholesterol-fighting drugs Zetia and Vytorin -- but its results did quite the opposite. |
Chemistry World
August 27, 2015
Phillip Broadwith |
Drugs in a class of their own In the last month, three drugs in new therapeutic classes have been approved for cardiovascular diseases. |
BusinessWeek
April 19, 2004
Catherine Arnst |
Cholesterol: How Low Should It Be? New studies say as low as possible, but drugs aren't for everybody |
The Motley Fool
January 17, 2008
Michael P. Cecil |
2 Sources of Trouble for Vytorin You know that a drug study has gone very, very bad when you can't find out its results without a congressional inquiry. |
Pharmaceutical Executive
February 1, 2009
Walter Armstrong |
Brand of the Year: Crestor For aiming to be a game-changer in cardiovascular disease, we recognize comeback kid Crestor as the year's No. 1. Plus three fine finalists. |
Managed Care
November 2004
Martin Sipkoff |
OTC Status for Low-Dose Lovastatin Would Have Widespread Implications The FDA stands poised to approve OTC low-dose statins, following a similar change in United Kingdom. |
The Motley Fool
November 15, 2011
Brian Orelli |
Good Data, Big Drug Market, but Still Risky Eli Lilly's evacetrapib is behind Roche and Merck. |
The Motley Fool
November 16, 2009
Brian Orelli |
Abbott Puts a Nail in Merck's Coffin There's a clear winner from the American Heart Association conference. |
BusinessWeek
November 22, 2004
Barrett & Carey |
Wondering About A Wonder Drug While the benefits of statins, sold under names such as Lipitor and Zocor, are well established, some doctors argue that their side effects have not received adequate scrutiny. |
HHMI Bulletin
May 2011
Sarah C. P. Williams |
The Next Statin Although clinicians have firmly established the link between cholesterol levels and heart disease, there are still more questions than answers when it comes to the nitty-gritty molecular details of this connection. |
BusinessWeek
December 13, 2004
Kate Murphy |
Cholesterol: The Bigger the Better Many doctors are convinced that getting a more thorough cholesterol test, one that identifies the types of LDL particles, can improve treatment and save lives. |
American Family Physician
March 15, 2005 |
What Should I Know About Cholesterol? A patient hand-out on how cholesterol levels effect the likelihood of heart attack and stroke. |
BusinessWeek
January 17, 2008
John Carey |
In the Real World, a Slew of Side Effects from Statins In clinical trials of statins, side effects were relatively rare. But many doctors believe they are more common in the real world. |
American Family Physician
January 15, 2001 |
Goals for Lowering Your Cholesterol Why is it important to have a normal cholesterol level?... What does the term "total cholesterol" mean?... Why is LDL called the "bad" cholesterol?... What are normal cholesterol levels?... How can I reduce my LDL and total cholesterol levels?... etc. |
Health
January 2008
Jessica Snyder Sachs |
What You Must Know About Your Cholesterol Many of us are in the danger zone, and we don't realize it. What can we start to do right now to change that? |
Chemistry World
June 2009
Derek Lowe |
Column: In the pipeline The author wonders about pharmaceutical companies' motives for collaboration |
Chemistry World
February 19, 2013
Andrew Turley |
Merck resolves Vytorin case for $688m Merck & Co has agreed to pay $688 million to settle claims that it failed to report clinical trial data relating to cholesterol brands Zocor (simvastatin) and Vytorin (ezetimibe, simvastatin). |
Chemistry World
August 16, 2013
Paola Quattroni |
Single molecule fights heart disease on two fronts Researchers in Israel have identified an antioxidant that can lower cholesterol levels as well as eliminating free radicals. This compound could be a promising alternative to statins, the most prescribed cholesterol-lowering drugs in the world. |
The Motley Fool
July 22, 2008
Brian Orelli |
Drug Duo SEAS Disappointment -- Again After numerous disappointments this year, Merck and Schering-Plough continue their string of bad luck. |
